Since the pandemic started to affect the Medistim business in second quarter of 2020, the effect has become gradually smaller, and in the second quarter of 2021, there was a strong rebound in procedures performed and hence in the sales revenues.
This rebound has continued throughout 2021, and Medistim has experienced strong growth in revenues due to the increase in number of CABG procedures performed. The sales growth was 17.6 % in NOK and operating profit (EBIT) growth was 21.8% in NOK. The Medistim Group’s sales for the full year 2021 ended at NOK 427.3 million (NOK 363.1 million). Currency neutral sales increased 24.6%.